190 related articles for article (PubMed ID: 26938643)
21. Adverse drug reactions & drug interactions in MDR-TB patients.
Gupta A; Kumar V; Natarajan S; Singla R
Indian J Tuberc; 2020 Dec; 67(4S):S69-S78. PubMed ID: 33308674
[TBL] [Abstract][Full Text] [Related]
22. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study.
Yang TW; Park HO; Jang HN; Yang JH; Kim SH; Moon SH; Byun JH; Lee CE; Kim JW; Kang DH
Medicine (Baltimore); 2017 Jul; 96(28):e7482. PubMed ID: 28700490
[TBL] [Abstract][Full Text] [Related]
23. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis.
Shin S; Furin J; Alcántara F; Hyson A; Joseph K; Sánchez E; Rich M
Chest; 2004 Mar; 125(3):974-80. PubMed ID: 15006956
[TBL] [Abstract][Full Text] [Related]
24. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.
Wu S; Zhang Y; Sun F; Chen M; Zhou L; Wang N; Zhan S
Am J Ther; 2016; 23(2):e521-30. PubMed ID: 24284652
[TBL] [Abstract][Full Text] [Related]
25. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
[TBL] [Abstract][Full Text] [Related]
26. [THE FREQUENCIES AND MANAGEMENT OF ADVERSE REACTIONS IN MULTI-DRUG RESISTANT TUBERCULOSIS TREATMENT].
Sasaki Y; Yoshiyama T; Okumura M; Morimoto K; Miyamoto M; Irina ; Yoshimori K; Kurashima A; Ogata H; Gotoh H
Kekkaku; 2017 Jan; 92(1):11-19. PubMed ID: 30646468
[TBL] [Abstract][Full Text] [Related]
27. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
[TBL] [Abstract][Full Text] [Related]
28. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
29. Effects of Multidrug Resistant Tuberculosis Treatment on Patients' Health Related Quality of Life: Results from a Follow Up Study.
Ahmad N; Javaid A; Syed Sulaiman SA; Basit A; Afridi AK; Jaber AA; Khan AH
PLoS One; 2016; 11(7):e0159560. PubMed ID: 27467560
[TBL] [Abstract][Full Text] [Related]
30. Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study.
Zhang Y; Wu S; Xia Y; Wang N; Zhou L; Wang J; Fang R; Sun F; Chen M; Zhan S
Med Sci Monit; 2017 May; 23():2348-2356. PubMed ID: 28520704
[TBL] [Abstract][Full Text] [Related]
31. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
Ramma L; Nhokwara PT; Rogers C
S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
[TBL] [Abstract][Full Text] [Related]
32. A cross-sectional study about knowledge and attitudes toward multidrug-resistant and extensively drug-resistant tuberculosis in a high-burden drug-resistant country.
Javed H; Tahir Z; Hashmi HJ; Jamil N
Int J Mycobacteriol; 2016 Jun; 5(2):128-34. PubMed ID: 27242222
[TBL] [Abstract][Full Text] [Related]
33. Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study.
Massud A; Syed Sulaiman SA; Ahmad N; Shafqat M; Chiau Ming L; Khan AH
Front Pharmacol; 2022; 13():883483. PubMed ID: 35747749
[TBL] [Abstract][Full Text] [Related]
34. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.
Baghaei P; Tabarsi P; Dorriz D; Marjani M; Shamaei M; Pooramiri MV; Mansouri D; Farnia P; Masjedi M; Velayati A
Am J Ther; 2011; 18(2):e29-34. PubMed ID: 20019591
[TBL] [Abstract][Full Text] [Related]
35. Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon.
Mpoh MM; Deli V; Daniel TT; Salvo F
Int J Mycobacteriol; 2023; 12(2):168-174. PubMed ID: 37338479
[TBL] [Abstract][Full Text] [Related]
36. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
[TBL] [Abstract][Full Text] [Related]
37. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
Dela AI; Tank NKD; Singh AP; Piparva KG
Lung India; 2017; 34(6):522-526. PubMed ID: 29098997
[TBL] [Abstract][Full Text] [Related]
38. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Bhushan B; Chander R; Kajal NC; Ranga V; Gupta A; Bharti H
Indian J Tuberc; 2014 Oct; 61(4):318-24. PubMed ID: 25675695
[TBL] [Abstract][Full Text] [Related]
39. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
J Antimicrob Chemother; 2017 Jul; 72(7):1871-1879. PubMed ID: 28419314
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda.
Ategyeka PM; Muhoozi M; Naturinda R; Kageni P; Namugenyi C; Kasolo A; Kisaka S; Kiwanuka N
BMC Infect Dis; 2023 Mar; 23(1):149. PubMed ID: 36899299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
